Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
0 competitors in Primary Prevention of Atherosclerotic Cardiovascular Disease
View Full LandscapeTarget Indication
Primary Prevention of Atherosclerotic Cardiovascular Disease
Clinical Trial
NCT05739383Last updated: 10/16/2026
No patent data available. Pre-approval drugs may not have Orange Book listings.
Leqvio
Leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
View on EMA